不同剂量缬沙坦延缓糖尿病肾病进展的效果初评  

Different Doses of Valsartan Delayed Progression of Diabetic Nephropathy in the Initial Evaluation of the Effect

作　　者：刘志远[1] 池本香[1] 张丽娟[1] 王守坚 陆伟伟[1] 

机构地区：[1]江苏省泗洪县分金亭医院肾内科,江苏泗洪223900

出　　处：《糖尿病新世界》2015年第14期177-178,共2页Diabetes New World Magazine

摘　　要：目的观察缬沙坦对糖尿病肾病患者临床治疗效果和安全情况。方法将该研究组收治糖尿病肾病患者随机分为对照组、缬沙坦80 mg和160 mg治疗组,记录施治前后各项指标。结果缬沙坦160 mg治疗组的尿蛋白下降及收缩压下降情况较另外2组显著。结论缬沙坦能够改善糖尿病肾病患者的尿蛋白、血压和肾功能,且缬沙坦治疗剂量达到160 mg时更具优越作用。Objective To observe the valsartan on clinical outcomes in patients with diabetic nephropathy and security situation. Methods In this study, patients with kidney disease were randomly divided into a control group treated diabetic group, valsartan 80 mg and 160 mg treatment group recorded blood pressure, blood urea nitrogen, creatinine, 24 h urinary protein, serum albumin and other indicators before and after treatment. Results Treatment with valsartan 160 mg group systolic blood pressure decreased urinary protein loss and the situation than the other two groups significantly; all patients plasma valsartan albumin increased. Conclusion Valsartan can improve urinary protein in patients with diabetic nephropathy, blood pressure and renal function, and valsartan dose of more favorable effect when 160mg.

关 键 词：缬沙坦 糖尿病肾病 高血压 蛋白尿 

分 类 号：R587[医药卫生—内分泌]